Oncologist:老年侵袭性非霍奇金淋巴瘤(NHL)的临床结局、治疗毒性和医疗保健利用

2021-08-13 yd2015 MedSci原创

尽管平衡治疗效果和并发症风险对于老年侵袭性非霍奇金淋巴瘤(NHL)患者至关重要,但很少有研究描述这些患者的临床结局、毒性率和医疗保健利用率。因此,来自美国的研究团队开展了回顾性研究,评估≥65岁

尽管平衡治疗效果和并发症风险对于老年侵袭性非霍奇金淋巴瘤(NHL)患者至关重要,但很少有研究描述这些患者的临床结局、毒性率和医疗保健利用率。因此,来自美国的研究团队开展了回顾性研究,评估≥65岁侵袭性非霍奇金淋巴瘤(NHL)患者治疗开始6个月的临床特征、预后、治疗毒性、非计划住院率和ICU住院率。相关结果发表在Oncologist杂志上。

研究纳入295例患者,中位年龄为73岁(范围65 - 100岁); 96/295或32.5%的患者年龄在65岁至69岁之间;77/295或26.1%的患者年龄在70 - 74岁;59/295人(20.0%)的患者年龄在75 - 79岁;63/295(21.4%)患者为80岁以上。大多数患者接受CHOP治疗(194/295,65.8%),其次是EPOCH(50/295, 17.0%)和mini-CHOP(27/295, 9.2%),均伴或不伴利妥昔单抗。大约五分之一(53/295,18.0%)的患者接受了中枢神经系统预防。大多数患者(201/295,68.1%)接受了6个周期的全身治疗,大约4.5个月的治疗。

               治疗和预后

总人群的ORR为86.9%(253/291),完全缓解(CR)率为84.2%(245/291)。中位随访时间为5.9年(3.8-8.4年),5年OS率为74.2%(95%CI68.4 -79.1)。

治疗后3-5级非血液学毒性的发生率为42.4%(125/295),4-5级非血液学毒性的发生率为8.1%(24/295)。在3-5级非血液学毒性中,最常见的包括发热性中性粒细胞减少(40.0%)和感染(33.6%)。3.9%(10/295)的患者因治疗毒性死亡,最常见的死亡原因是感染。总体而言,41.0%(121/295)的患者在治疗开始后的前6个月内意外入院,6.1%(18/295)的患者在治疗开始后的前6个月内入住ICU。在可评估的首次非计划住院患者中(n = 121),最常见的住院原因是发热性中性粒细胞减少(41.3%),其次是感染(28.1%),其他非癌症用药情况(13.2%)和症状(9.1%)。在所有患者中,14.9%(44/295)有治疗剂量减少和/或延迟。

                    3-5级毒性相关因素

年龄在65-69岁、70-74岁、75-79岁和80岁以上的患者中,5年OS率分别为82.2% (95%CI, 72.4 -88.7)、72.0% (95%CI,59.7- 81.1)、73.6%(95%CI,59.2-83.6)和66.4%(95% CI, 52.5-77.0)。3-5级非血液学毒性分别为35.4%(34/96)、46.8%(36/77)、50.9%(30/59)和39.7%(25/63),4- 5级非血液学毒性分别为3.1%(3/96)、9.1%(7/77)、8.5%(5/59)和14.3%(9/63)。治疗开始后的前6个月内意外入院率分别为34.4%(33/96),45.5%(35/77),47.5%(28/59)和39.7%(25/63)。在治疗开始后的前6个月内入住ICU率分别为3.1%(3/96),5.2%(4/77),6.8%(4/59)和11.1% (7/63)。剂量减少率和/或剂量延迟率分别为12.5%(12/96)、16.9%(13/77)、13.6%(8/59)和17.5%(11/63)。

在多变量模型(n = 286)中,低白蛋白血症(OR, 4.29;95%CI, 2.12- 8.68;p<0.001)和高共病评分(OR, 4.22;95%CI, 1.90-9.36;p<0.001)都与更容易出现3-5级非血液学毒性。

          非计划住院的相关因素

在多变量模型(n = 286)中,低白蛋白血症(OR, 2.83;95%CI,1.43 -5.58;p = 0.003),高共病评分(OR, 3.93, 95% CI, 1.82-8.49;p = 0.001), EPOCH联合或不联合利妥昔单抗治疗方案(OR, 5.45;95%CI, 1.45-20.5;P =0.012)与高开始治疗后的前6个月计划外住院率相关。

综上,老年侵袭性非霍奇金淋巴瘤(NHL)治疗大部分存活超过5年,也有近一半患者经历毒性以及非计划住院。因此,对于这部分患者需要加强临床干预。

原始出处:

Johnson PC, Yi A, Horick N,et al. Clinical Outcomes, Treatment Toxicity, and Health Care Utilization in Older Adults with Aggressive Non-Hodgkin Lymphoma. Oncologist. 2021 Jul 29. doi: 10.1002/onco.13915. Epub ahead of print. PMID: 34327767.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1866196, encodeId=7a911866196cd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 01 01:30:24 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843266, encodeId=ce70184326642, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 17 06:30:24 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366390, encodeId=f9fd13663905c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455179, encodeId=58b914551e902, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493234, encodeId=5e9514932349d, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525906, encodeId=67f91525906df, content=<a href='/topic/show?id=22a03480efa' target=_blank style='color:#2F92EE;'>#医疗保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34807, encryptionId=22a03480efa, topicName=医疗保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb511671747, createdName=drj2007, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038400, encodeId=2d7910384004a, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Aug 14 00:30:24 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2022-03-01 docwu2019
  2. [GetPortalCommentsPageByObjectIdResponse(id=1866196, encodeId=7a911866196cd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 01 01:30:24 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843266, encodeId=ce70184326642, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 17 06:30:24 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366390, encodeId=f9fd13663905c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455179, encodeId=58b914551e902, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493234, encodeId=5e9514932349d, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525906, encodeId=67f91525906df, content=<a href='/topic/show?id=22a03480efa' target=_blank style='color:#2F92EE;'>#医疗保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34807, encryptionId=22a03480efa, topicName=医疗保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb511671747, createdName=drj2007, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038400, encodeId=2d7910384004a, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Aug 14 00:30:24 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1866196, encodeId=7a911866196cd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 01 01:30:24 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843266, encodeId=ce70184326642, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 17 06:30:24 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366390, encodeId=f9fd13663905c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455179, encodeId=58b914551e902, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493234, encodeId=5e9514932349d, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525906, encodeId=67f91525906df, content=<a href='/topic/show?id=22a03480efa' target=_blank style='color:#2F92EE;'>#医疗保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34807, encryptionId=22a03480efa, topicName=医疗保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb511671747, createdName=drj2007, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038400, encodeId=2d7910384004a, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Aug 14 00:30:24 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-15 sunyl07
  4. [GetPortalCommentsPageByObjectIdResponse(id=1866196, encodeId=7a911866196cd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 01 01:30:24 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843266, encodeId=ce70184326642, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 17 06:30:24 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366390, encodeId=f9fd13663905c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455179, encodeId=58b914551e902, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493234, encodeId=5e9514932349d, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525906, encodeId=67f91525906df, content=<a href='/topic/show?id=22a03480efa' target=_blank style='color:#2F92EE;'>#医疗保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34807, encryptionId=22a03480efa, topicName=医疗保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb511671747, createdName=drj2007, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038400, encodeId=2d7910384004a, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Aug 14 00:30:24 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-15 july_977
  5. [GetPortalCommentsPageByObjectIdResponse(id=1866196, encodeId=7a911866196cd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 01 01:30:24 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843266, encodeId=ce70184326642, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 17 06:30:24 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366390, encodeId=f9fd13663905c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455179, encodeId=58b914551e902, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493234, encodeId=5e9514932349d, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525906, encodeId=67f91525906df, content=<a href='/topic/show?id=22a03480efa' target=_blank style='color:#2F92EE;'>#医疗保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34807, encryptionId=22a03480efa, topicName=医疗保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb511671747, createdName=drj2007, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038400, encodeId=2d7910384004a, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Aug 14 00:30:24 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-15 yzh402
  6. [GetPortalCommentsPageByObjectIdResponse(id=1866196, encodeId=7a911866196cd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 01 01:30:24 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843266, encodeId=ce70184326642, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 17 06:30:24 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366390, encodeId=f9fd13663905c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455179, encodeId=58b914551e902, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493234, encodeId=5e9514932349d, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525906, encodeId=67f91525906df, content=<a href='/topic/show?id=22a03480efa' target=_blank style='color:#2F92EE;'>#医疗保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34807, encryptionId=22a03480efa, topicName=医疗保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb511671747, createdName=drj2007, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038400, encodeId=2d7910384004a, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Aug 14 00:30:24 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
  7. [GetPortalCommentsPageByObjectIdResponse(id=1866196, encodeId=7a911866196cd, content=<a href='/topic/show?id=16ce133504e' target=_blank style='color:#2F92EE;'>#Oncol#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13350, encryptionId=16ce133504e, topicName=Oncol)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a12645, createdName=docwu2019, createdTime=Tue Mar 01 01:30:24 CST 2022, time=2022-03-01, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1843266, encodeId=ce70184326642, content=<a href='/topic/show?id=3d052296e4e' target=_blank style='color:#2F92EE;'>#临床结局#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22967, encryptionId=3d052296e4e, topicName=临床结局)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=7fbd46, createdName=mei531, createdTime=Thu Feb 17 06:30:24 CST 2022, time=2022-02-17, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1366390, encodeId=f9fd13663905c, content=<a href='/topic/show?id=186126998e2' target=_blank style='color:#2F92EE;'>#侵袭性#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=26998, encryptionId=186126998e2, topicName=侵袭性)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=1be8234, createdName=sunyl07, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1455179, encodeId=58b914551e902, content=<a href='/topic/show?id=bebe8032fc' target=_blank style='color:#2F92EE;'>#GIST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=8032, encryptionId=bebe8032fc, topicName=GIST)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=6e445632366, createdName=july_977, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1493234, encodeId=5e9514932349d, content=<a href='/topic/show?id=b46f12e81ed' target=_blank style='color:#2F92EE;'>#NHL#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12781, encryptionId=b46f12e81ed, topicName=NHL)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f7839003589, createdName=yzh402, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1525906, encodeId=67f91525906df, content=<a href='/topic/show?id=22a03480efa' target=_blank style='color:#2F92EE;'>#医疗保健#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=35, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=34807, encryptionId=22a03480efa, topicName=医疗保健)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8eb511671747, createdName=drj2007, createdTime=Sun Aug 15 12:30:24 CST 2021, time=2021-08-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1038400, encodeId=2d7910384004a, content=谢谢梅斯分享这么多精彩信息, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f0620, createdName=anti-cancer, createdTime=Sat Aug 14 00:30:24 CST 2021, time=2021-08-14, status=1, ipAttribution=)]
    2021-08-14 anti-cancer

    谢谢梅斯分享这么多精彩信息

    0